Northern Trust Corp Sells 233,675 Shares of Takeda Pharmaceutical Co. $TAK

Northern Trust Corp lessened its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 12.5% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,639,913 shares of the company’s stock after selling 233,675 shares during the quarter. Northern Trust Corp owned approximately 0.05% of Takeda Pharmaceutical worth $24,386,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. FNY Investment Advisers LLC bought a new position in Takeda Pharmaceutical in the 1st quarter valued at $37,000. Farther Finance Advisors LLC grew its position in shares of Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after buying an additional 1,045 shares in the last quarter. Fifth Third Bancorp grew its position in shares of Takeda Pharmaceutical by 85.5% during the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock worth $78,000 after buying an additional 2,411 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Takeda Pharmaceutical during the 4th quarter worth $94,000. Finally, GAMMA Investing LLC grew its position in shares of Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after buying an additional 1,296 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.1%

Shares of NYSE TAK opened at $14.99 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The stock has a market capitalization of $47.68 billion, a P/E ratio of 49.95 and a beta of 0.22. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.56. The business has a fifty day moving average price of $14.81 and a 200 day moving average price of $14.75.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Equities research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.